Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

SERTOLI TREATED CORD BLOOD FOR SPINAL CORD INJURY

Award Number: R43NS050065
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/24/2004
PERIOD OF PERFORMANCE END DATE: 03/31/2005

Group Awards By:

View Award Description

SERTOLI TREATED CORD BLOOD FOR SPINAL CORD INJURY - DESCRIPTION (provided by applicant): Stem cells from human umbilical cord blood (hUCB) represent a promising cellular therapeutic strategy for the treatment of cord injury (SCI). These cells are capable of differentiating into neurons and glia in vivo, engraft into specific sites of neurological injury, and produce recovery of function in rats following SCI. However, many cells die following cryopreservation, an essential processing step for storage of a cellular therapeutic product, and/or subsequently, following transplantation. The testis-derived Sertofi cells (SCs) and Sertoli cell conditioned media (SCM) have been shown to enhance the viability of cells post-thaw prior to transplantation, thereby increasing the likelihood of cell survival and therapeutic effect post-transplant. Treating the Hucb cells with SCM may provide the advantage that Saneron CCEL Therapeutics, Inc, is seeking in order to develop a marketable product for a cellular therapeutic treatment in SCI. The unknown is whether the optimal modification of hUBC utilizes rat- or human-based SCM. This Phase I research program is designed to define the optimal modification of hUBC processing and to determine the timing of SCM-treated hUCB cells that produces optimal behavioral recovery in an animal model of SCL The successful enhancement of cell viability, identification of the determinant factor of the enhancement, and the determination of the optimal timing of hUCB cells with SCM have important implications for the development of a cellular therapy for SCI and the therapeutic potential of stem cells in human cell transplantation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2004 ( Subtotal = $150,000 )
2004	2004	SANERON CCEL THERAPEUTICS INC	13101 TELECOM DRIVE	TAMPA	FL	33637	HILLSBOROUGH	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/22/2004	NEW	$150,000
														Subtotal = $150,000

Grand Total All Awards = $150,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SERTOLI TREATED CORD BLOOD FOR SPINAL CORD INJURY

Award Number: R43NS050065

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/24/2004

PERIOD OF PERFORMANCE END DATE: 03/31/2005

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer